Topic · Hematology · Medicine

Chronic Myeloid Leukemia Treatments

OpenAlex topic; a paper is listed when OpenAlex scores it at least 0.5 for this topic.

8 papers

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano, Belen Zamora-Valdivieso, Sara Pérez-Gutiérrez, Andrea Olarte-San Juan, Alba Díaz-Aguilera, Sonsoles Calvo-Jimenez, Nuria Calzada, Alberto Fernández‐Medarde, Magdalena Sierra, Fermin M. Sanchez-Guijo, Dolors Colomer, Robyn L. Schenk, Marco H. Hofmann, , Eugenio Santos

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

Cell Death and Disease · Aug 12, 2026Peer-reviewedCancer Biology

Proximity-induced rewiring of oncogenic kinase triggers apoptosis

Manuel L. Merz, Veronika M. Shoba, Rajaiah Pergu, Zachary C. Severance, Dhanushka N. P. Munkanatta Godage, Arghya Deb, Hui Si Kwok, Prashant R. Singh, Sameek Singh, Jonathan B. Allen, Wenzhi Tian, Pallavi M. Gosavi, Santosh Kumar Chaudhary, Viktoriya S. Anokhina, Ellen Weisberg, , Amit Choudhary

This paper develops a small molecule, BRD8833, that induces BCR-ABL phosphorylation to disrupt its active site electric field, leading to loss of hyperactivity and apoptosis in BCR-ABL-dependent cancer cells.

ACS Central Science · Apr 9, 2026Peer-reviewedSynthetic Biology

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance

Owen F.J. Hovey, Mallory I. Frederick, Quan M. Quach, Jenica H. Kakadia, Alyssa Wu, Kyle Yang, Tingting Wu, Xiang Ruan, Tomonori Kaneko, Courtney Voss, Ilka U. Heinemann, Shawn S.‐C. Li

This study identifies LIN28A as a mediator of imatinib resistance in CML by reprogramming the kinome and phosphoproteome, with potential therapeutic implications for overcoming resistance.

Molecular & Cellular Proteomics · Jan 20, 2026Peer-reviewedCancer Biology

A computational dynamic model of combination treatment for type II inhibitors with asciminib

J. Roadnight Sheehan, Astrid Silvia de Wijn, Ran Friedman

The paper develops a computational model to evaluate combination treatments of type II Abl1 inhibitors and asciminib, introducing ERICcombo to assess synergy and effectiveness at patient-relevant concentrations.

Protein Science · Jul 17, 2025Peer-reviewedCancer Biology

Autophosphorylation of the oncogenic protein TEL-ABL confers resistance to the allosteric ABL inhibitor asciminib

Serena Muratcioğlu, Christopher A. Eide, Chien‐Lun Hung, Kent Gorday, Emily Sumpena, Wenqi Zuo, Jay T. Groves, Brian J. Druker, John Kuriyan

The paper shows that phosphorylation of TEL-ABL makes it resistant to asciminib, but dephosphorylation restores sensitivity.

Science Signaling · Jul 15, 2025Peer-reviewedBiochemistry

Studying the age of onset and detection of Chronic Myeloid Leukemia using a three-stage stochastic model

Suryadeepto Nag, Ananda Shikhara Bhat, Siddhartha Pratim Chakrabarty

This paper develops a three-stage stochastic model of CML progression and validates it against age incidence data, then proposes a framework to estimate the time of malignancy onset from cancer detection.

Journal of Biological Systems · Feb 24, 2024Peer-reviewedSystems Biology

Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy

Jonathan Rodriguez, Abdon Iniguez, Nilamani Jena, Prasanthi V. Tata, Zhongying Liu, Arthur D. Lander, John S. Lowengrub, Richard A. Van Etten

This paper develops a nonlinear mathematical model of CML hematopoiesis to predict TKI therapy responses and identifies strategies to improve treatment outcomes.

eLife · Apr 28, 2023Peer-reviewedSystems Biology

Early Dynamics of Chronic Myeloid Leukemia on Nilotinib Predicts Deep Molecular Response

Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi Kajita, Shinji Nakaoka, Mayuko Tsuda, Keiji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, , Kazuyuki Aihara

This paper develops a mathematical model using early clinical data to predict deep molecular response in CML patients treated with nilotinib.

npj Systems Biology and Applications · Oct 13, 2022Peer-reviewedSystems Biology